Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DRUG DISCOVERY

Choosing your druggability battle

Nature Chemical Biology volume 15, pages 652–653 (2019)Cite this article

Subjects

The advent of PROTACs that degrade the entire protein target rather than simply inhibiting it bring druggable yet apparently non-functional binding sites into play for medicinal chemists to do their work.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: SMARCA2 presents two domains: the druggable bromodomain and the functional ATPase domain.

References

  1. Filippakopoulos, P. et al. Nature 468, 1067–1073 (2010).

    Article  CAS  Google Scholar 

  2. Smith, S. G. & Zhou, M.-M. ACS Chem. Biol. 11, 598–608 (2016).

    Article  CAS  Google Scholar 

  3. Kadoch, C. & Crabtree, G. R. Sci. Adv. 1, e1500447 (2015).

    Article  Google Scholar 

  4. Vangamudi, B. et al. Cancer Res. 75, 3865–3878 (2015).

    Article  CAS  Google Scholar 

  5. Papillon, J. P. N. et al. J. Med. Chem. 61, 10155–10172 (2018).

    Article  CAS  Google Scholar 

  6. Farnaby, W. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0294-6 (2019).

  7. Toure, M. & Crews, C. M. Angew. Chem. Int. Edn Engl. 55, 1966–1973 (2016).

    Article  CAS  Google Scholar 

  8. Zengerle, M., Chan, K. H. & Ciulli, A. ACS Chem. Biol. 10, 1770–1777 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Discovery Network Group, Pfizer Medicine Design, Cambridge, MA, USA

    Dafydd Owen

Authors
  1. Dafydd Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dafydd Owen.

Ethics declarations

Competing interests

Dafydd Owen is a shareholder in Pfizer Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Owen, D. Choosing your druggability battle. Nat Chem Biol 15, 652–653 (2019). https://doi.org/10.1038/s41589-019-0305-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41589-019-0305-7

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research